---
input_text: Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle
  cell disease.Sickle cell disease (SCD) is a group of inherited genetic conditions
  associated with lifelong complications and increased healthcare resource utilization.
  Standard treatment for SCD in the US varies based on stage of the disease and observed
  clinical severity. In this study, we aim to evaluate the potential cost-effectiveness
  of a durable cell or gene therapy cure for sickle cell disease from the US healthcare
  sector perspective. We developed a lifetime Markov model to evaluate the cost-effectiveness
  of a hypothetical single-administration durable treatment (DT) for SCD provided
  at birth, relative to standard of care (SOC). We informed model inputs including
  direct healthcare costs, health state utility weights, transition probabilities,
  and mortality rates using a retrospective database analysis of commercially insured
  individuals and the medical literature. Our primary outcome of interest was the
  incremental cost-effectiveness ratio (ICER) of DT versus SOC evaluated at a base
  case willingness-to-pay (WTP) threshold of $150,000 per quality-adjusted life year
  (QALY). We tested the robustness of our base case findings through scenario, deterministic
  sensitivity (DSA), and probabilistic sensitivity analyses (PSA). In the base case
  analysis, treatment with DT was cost-effective with an ICER of $140,877/QALY relative
  to SOC for a hypothetical cohort involving 47% females. Both males (ICER of $135,574/QALY)
  and females (ICER of $146,511/QALY) were similarly cost-effective to treat. In univariate
  DSA the base case ICER was most sensitive to the costs of treating males, DT treatment
  cost, and the discount rate. In PSA, DT was cost-effective in 32.7%, 66.0%, and
  92.6% of 10,000 simulations at WTP values of $100,000, $150,000, and $200,000 per
  QALY, respectively. A scenario analysis showed cost-effectiveness of DT is highly
  contingent on assumed lifetime durability of the cure. A hypothetical cell or gene
  therapy cure for SCD is likely to be cost-effective from the US healthcare sector
  perspective. Large upfront costs of a single administration cure are offset by significant
  downstream gains in health for patients treated early in life. We find cost-effectiveness
  outcomes do not vary substantially by gender; however, several model parameters
  including assumed durability and upfront cost of DT are likely to influence cost-effectiveness
  findings.
raw_completion_output: |-
  primary_disease: Sickle cell disease (SCD)

  medical_actions: treatment with DT; standard of care (SOC); single-administration durable treatment; retrospective database analysis; incremental cost-effectiveness ratio (ICER) calculation; scenario analysis; deterministic sensitivity analysis (DSA); probabilistic sensitivity analysis (PSA)

  symptoms: lifelong complications; increased healthcare resource utilization

  chemicals: 

  action_annotation_relationships: single-administration durable treatment TREATS lifelong complications IN Sickle cell disease (SCD); single-administration durable treatment TREATS increased healthcare resource utilization IN Sickle cell disease (SCD); retrospective database analysis ANALYZES Sickle cell disease (SCD); incremental cost-effectiveness ratio (ICER) calculation EVALUATES treatment effectiveness IN Sickle cell disease (SCD); scenario analysis EVALUATES treatment durability IN Sickle cell disease (SCD); deterministic sensitivity analysis (DSA) EVALUATES cost-effectiveness sensitivity IN Sickle cell disease (SCD); probabilistic sensitivity analysis (PSA) EVALUATES treatment cost-effectiveness probability IN Sickle cell disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  probabilistic sensitivity analysis (PSA) EVALUATES treatment cost-effectiveness probability IN Sickle cell disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - treatment with DT
    - standard of care (SOC)
    - single-administration durable treatment
    - retrospective database analysis
    - incremental cost-effectiveness ratio (ICER) calculation
    - scenario analysis
    - deterministic sensitivity analysis (DSA)
    - probabilistic sensitivity analysis (PSA)
  symptoms:
    - lifelong complications
    - increased healthcare resource utilization
  action_annotation_relationships:
    - subject: single-administration durable treatment
      predicate: TREATS
      object: lifelong complications
      qualifier: MONDO:0007374
    - subject: <single-administration durable treatment>
      predicate: <TREATS>
      object: <increased healthcare resource utilization>
      qualifier: MONDO:0007374
      subject_extension: <single-administration durable treatment>
    - subject: retrospective database analysis
      predicate: ANALYZES
      object: HP:0007760
    - subject: incremental cost-effectiveness ratio (ICER) calculation
      predicate: EVALUATES
      object: treatment effectiveness
      qualifier: MONDO:0007374
    - subject: scenario analysis
      predicate: EVALUATES
      object: treatment durability
      qualifier: MONDO:0011382
    - subject: deterministic sensitivity analysis
      predicate: EVALUATES
      object: cost-effectiveness sensitivity
      qualifier: MONDO:0011382
    - subject: probabilistic sensitivity analysis
      predicate: EVALUATES
      object: treatment cost-effectiveness probability
      qualifier: MONDO:0011382
named_entities:
  - id: MONDO:0011382
    label: Sickle Cell Anemia
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000756
    label: blood transfusion
  - id: CHEBI:33281
    label: antibiotics
  - id: HP:0001944
    label: dehydration
  - id: HP:0007760
    label: Sickle Cell Disease (SCD) symptoms
  - id: HP:0012592
    label: Albuminuria
  - id: HP:0012622
    label: Chronic kidney disease
  - id: HP:0100543
    label: cognitive deficits
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0002863
    label: myelodysplastic syndrome
  - id: HP:0004808
    label: acute myeloid leukemia
  - id: CHEBI:28901
    label: busulfan
  - id: HP:0010972
    label: Ineffective erythropoiesis
  - id: HP:0001878
    label: Hemolytic anemia
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:35143
    label: Hemoglobin (HbS)
  - id: CHEBI:44423
    label: hydroxycarbamide
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: MONDO:0002120
    label: Nasopharyngeal neuroendocrine carcinoma (NEC)
  - id: HP:0030828
    label: wheeze
  - id: HP:0012735
    label: cough
  - id: MONDO:0003664
    label: Haemolytic anaemias
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0025464
    label: Oxidative stress
  - id: CHEBI:17627
    label: Haem
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:197439
    label: TNFalpha
  - id: MAXO:0000149
    label: haploidentical hematopoietic cell transplant (HCT)
  - id: MONDO:0005570
    label: Blood disorders
  - id: HP:0002617
    label: Vasculopathy
  - id: HP:0010885
    label: Bone infarctions
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0001945
    label: fever
  - id: HP:0033050
    label: sore throat
  - id: HP:0002315
    label: headache
  - id: HP:0001394
    label: Cirrhosis
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0001297
    label: Stroke
  - id: HP:0031033
    label: Renal acidification defect
  - id: HP:0032632
    label: Renal papillary necrosis
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: HP:0012213
    label: Decreased glomerular filtration rate (GFR)
  - id: CHEBI:59163
    label: biomarkers
  - id: MAXO:0000915
    label: Standardized polysomnography (PSG)
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0034312
    label: Nocturnal hypoxemia
  - id: CHEBI:35482
    label: opioid analgesics
  - id: MONDO:0005148
    label: type II diabetes
  - id: MAXO:0000058
    label: Pharmacotherapy
  - id: MAXO:0000457
    label: Pain management
  - id: CHEBI:18050
    label: L-glutamine
  - id: HP:0004421
    label: Elevated systolic blood pressure
  - id: HP:0030515
    label: Moderate visual impairment
  - id: HP:0000618
    label: Blindness
  - id: CHEBI:68579
    label: rivaroxaban
  - id: CHEBI:24261
    label: glucocorticoids
  - id: HP:0012532
    label: Chronic pain
  - id: CHEBI:6121
    label: Ketamine
  - id: MONDO:0010631
    label: Acute ischemic priapism (IP)
  - id: CHEBI:8093
    label: Phenylephrine
  - id: CHEBI:35480
    label: Analgesics
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: CHEBI:25555
    label: Nitrogen
  - id: HP:0001396
    label: Cholestasis
  - id: HP:0000083
    label: Kidney failure
  - id: CHEBI:50858
    label: Corticosteroids
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000494
    label: Blood pressure monitoring
  - id: HP:0003006
    label: lack of universal newborn screening (NBS)
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0001873
    label: Thrombocytopenia
  - id: MONDO:0100096
    label: COVID-19
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: MAXO:0000861
    label: Labor induction
  - id: HP:0100602
    label: Preeclampsia
  - id: CHEBI:16199
    label: Urea
  - id: CHEBI:16737
    label: Creatinine
  - id: MAXO:0000748
    label: Fecal microbiota transplantation (FMT)
  - id: CHEBI:17968
    label: Butyrate
  - id: CHEBI:31011
    label: Valerate
  - id: CHEBI:17272
    label: Propionate
  - id: MONDO:0020121
    label: muscular dystrophy
  - id: HP:0002664
    label: cancer
  - id: HP:0000819
    label: diabetes
  - id: MONDO:0004992
    label: cancer
  - id: MONDO:0005015
    label: diabetes
  - id: MAXO:0000610
    label: Enzyme-linked immunosorbent assay
  - id: HP:0007018
    label: Attention deficits
  - id: HP:0000848
    label: Increased plasma renin
  - id: CHEBI:48432
    label: Angiotensin II
  - id: CHEBI:4784
    label: Enalapril
  - id: HP:0100749
    label: Chest pain
  - id: HP:0002094
    label: Shortness of breath
  - id: HP:0000716
    label: Depression
  - id: HP:0001627
    label: Cardiac abnormalities
  - id: MONDO:0042491
    label: Contrast-induced nephropathy (CIN)
  - id: HP:0003259
    label: Elevated serum creatinine (SCr)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: MONDO:0054550
    label: Avascular Necrosis of the Femoral Head (AVNFH)
  - id: MAXO:0000004
    label: surgical intervention
  - id: HP:0012531
    label: pain
  - id: HP:0000969
    label: oedema
  - id: HP:0002140
    label: Ischemic cerebrovascular accidents
  - id: HP:0002098
    label: respiratory distress
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: CHEBI:27690
    label: Acetazolamide (ACZ)
  - id: CHEBI:48021
    label: Peptide nucleic acid (PNA)
  - id: CHEBI:53374
    label: Poly Lactic-co-Glycolic Acid (PLGA)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:6443
    label: Levonorgestrel
  - id: HP:0001518
    label: Small for gestational age
  - id: HP:0001622
    label: Preterm
  - id: CHEBI:8735
    label: PAINReportIt(R)
  - id: MAXO:0000376
    label: liver biopsy
  - id: MAXO:0000066
    label: Oxygen supplementation
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0001395
    label: Liver fibrosis
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:9168
    label: sirolimus
  - id: HP:0011105
    label: Fluid overload
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0008209
    label: Premature ovarian insufficiency (POI)
  - id: CHEBI:28876
    label: Melphalan
  - id: MONDO:0019740
    label: HIV-associated thrombotic thrombocytopenic purpura (TTP)
  - id: MONDO:0005812
    label: Influenza
  - id: CHEBI:82594
    label: Ferritin
  - id: HP:0031417
    label: rhinorrhea
  - id: HP:0002027
    label: abdominal pain
  - id: HP:0025095
    label: sneezing
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:22587
    label: antiviral
  - id: MAXO:0001298
    label: therapy
  - id: MAXO:0009101
    label: early intervention
  - id: MONDO:0003847
    label: Genetic disorders
  - id: MAXO:0000079
    label: Genetic counseling
  - id: MAXO:0000530
    label: Carrier screening
  - id: HP:0004936
    label: venous thromboembolism
  - id: CHEBI:71942
    label: phosphodiesterase 5 inhibitor
  - id: MONDO:0010094
    label: Sickle Cell Trait (SCT)
  - id: MAXO:0000427
    label: Brain magnetic resonance imaging
  - id: HP:0004944
    label: Intracranial aneurysms
  - id: HP:0030447
    label: Sickle Cell-Related Multiple Chronic Conditions (MCC)
  - id: MAXO:0001077
    label: splenectomy
  - id: HP:0001896
    label: reticulocytopenia
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:64357
    label: rituximab
  - id: HP:0001513
    label: Obesity
  - id: HP:0001397
    label: Liver steatosis
  - id: HP:0003124
    label: Hypercholesterolemia
  - id: HP:0000822
    label: Hypertension
  - id: HP:0004308
    label: Ventricular arrhythmias
  - id: MAXO:0010203
    label: Echocardiography
  - id: MONDO:0002492
    label: Acute Kidney Injury (AKI)
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitors
  - id: HP:0031589
    label: Suicidal ideation
  - id: HP:0000789
    label: Infertility
  - id: CHEBI:22333
    label: alkylating agents
  - id: CHEBI:33699
    label: mRNA
  - id: MAXO:0000068
    label: Transplantation
  - id: HP:0000739
    label: anxiety
  - id: MONDO:0018585
    label: Pediatric Arterial Ischemic Stroke
  - id: HP:0025722
    label: cerebral infarcts
